Sailong Pharmaceutical Group Co.,Ltd. (SHE:002898)

SHE:002898 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	29.21	61.02	48.84	87.12	72.27	113.31
Trading Asset Securities	-	-	-	2.14	-	-
Cash & Short-Term Investments	29.21	61.02	48.84	89.26	72.27	113.31
Cash Growth	-11.43%	24.92%	-45.28%	23.51%	-36.22%	95.10%
Accounts Receivable	151.07	159.85	99.68	55.27	88.85	84.98
Other Receivables	6.79	19.91	4.03	14.71	19.68	33.83
Receivables	157.86	179.76	103.7	69.98	108.53	118.81
Inventory	111.23	80.38	94.08	88.87	63.97	52.98
Other Current Assets	75.97	23.55	3.21	8.19	9.59	4.05
Total Current Assets	374.27	344.7	249.83	256.3	254.36	289.14
Property, Plant & Equipment	342.21	347.37	402.23	352.11	394.25	405.59
Long-Term Investments	4.9	4.9	4.9	69.86	62.28	45.19
Other Intangible Assets	70.43	71.65	67.71	67	67.77	70.46
Long-Term Deferred Tax Assets	5.08	5.51	3.71	1.96	13.58	18.57
Long-Term Deferred Charges	39.29	38.86	59.16	45.74	36.7	33.23
Other Long-Term Assets	19.1	19.11	20.68	20.88	19.08	20.61
Total Assets	855.28	832.1	808.22	813.84	848.01	882.78

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	142.65	99.3	62.31	63.53	94.47	94.15
Accrued Expenses	5.63	43.31	21.03	17.55	22.39	14.55
Short-Term Debt	73.21	84.93	128.13	90.05	100.06	100.12
Current Portion of Long-Term Debt	30.02	21.64	6.27	11.9	29.63	28.86
Current Portion of Leases	-	3.72	0.5	0.36	0.24	0.89
Current Income Taxes Payable	17.71	7.07	-	0.02	0.75	0.74
Current Unearned Revenue	15.65	3.39	11.51	11.53	23.53	8.24
Other Current Liabilities	155.66	147	25.27	32.08	25.38	19.03
Total Current Liabilities	440.53	410.37	255.02	227.01	296.45	266.58
Long-Term Debt	7.5	8	29.86	25.08	13.32	42.91
Long-Term Leases	4.95	5.97	0.33	0.04	0.18	0.27
Long-Term Unearned Revenue	2.69	2.65	2.6	2.84	3.08	3.33
Long-Term Deferred Tax Liabilities	11.03	11.16	9.62	9.76	8.63	6.04
Other Long-Term Liabilities	10.62	9.81	11.51	13.23	-	-
Total Liabilities	477.34	447.95	308.95	277.96	321.67	319.12

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	176	176	176	176	176	176
Additional Paid-In Capital	288.58	288.58	288.47	288.47	288.47	288.47
Retained Earnings	-95.42	-86.42	34.75	71.41	61.88	99.19
Comprehensive Income & Other	2.33	2	0.06	-	-	-
Total Common Equity	371.49	380.15	499.28	535.88	526.35	563.66
Minority Interest	6.45	4.01	-	-	-	-
Shareholders' Equity	377.94	384.15	499.28	535.88	526.35	563.66
Total Liabilities & Equity	855.28	832.1	808.22	813.84	848.01	882.78

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	115.68	124.26	165.09	127.42	143.43	173.05
Net Cash (Debt)	-86.48	-63.24	-116.25	-38.16	-71.16	-59.74
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.49	-0.36	-0.66	-0.22	-0.40	-0.34
Filing Date Shares Outstanding	176	176	176	176	176	176
Total Common Shares Outstanding	176	176	176	176	176	176
Working Capital	-66.27	-65.66	-5.19	29.29	-42.09	22.57
Book Value Per Share	2.11	2.16	2.84	3.04	2.99	3.20
Tangible Book Value	301.06	308.5	431.56	468.89	458.58	493.21
Tangible Book Value Per Share	1.71	1.75	2.45	2.66	2.61	2.80
Buildings	-	271.16	301.56	311.75	335.26	323.12
Machinery	-	217.25	226.12	213.31	207.43	194.92
Construction In Progress	-	5.89	5.89	1.44	1.38	9.21

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error